📊 STRO Key Takeaways
Is Sutro Biopharma, Inc.. (STRO) a Good Investment?
Sutro Biopharma faces critical financial distress with negative stockholders' equity of -$66.9M and operating cash burn of -$43M annually, creating <2 year runway absent additional capital raises. While revenue growth of 65.2% YoY demonstrates commercial progress, the company is operating at massive losses (-265% net margin) with no clear near-term profitability trajectory, indicating unsustainable fundamentals.
Sutro Biopharma, Inc.. Key Strengths (STRO)
- Revenue growth of 65.2% YoY demonstrates commercial traction and market acceptance
- Adequate short-term liquidity with $73.7M cash and 3.12x current ratio
- Minimal debt burden with only $4.1M long-term debt reduces refinancing risk
STRO Stock Risks: Sutro Biopharma, Inc.. Investment Risks
- Negative stockholders' equity of -$66.9M indicates technical insolvency on book value basis
- Operating cash burn of -$43M annually against only $73.7M cash creates <2 year survival window
- Massive operating losses (-204% margin) with no demonstrated path to profitability despite revenue growth
- Company dependent on capital raises or dramatic operational turnaround for viability
Key Metrics to Watch
- Operating cash flow trajectory and progress toward cash flow breakeven
- Revenue growth sustainability and gross margin expansion as product scales
- Cash balance depletion rate and timing/need for additional equity financing
Sutro Biopharma, Inc.. (STRO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.12x current ratio provides a solid financial cushion.
STRO Profit Margin, ROE & Profitability Analysis
STRO vs Healthcare Sector: How Sutro Biopharma, Inc.. Compares
How Sutro Biopharma, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sutro Biopharma, Inc.. Stock Overvalued? STRO Valuation Analysis 2026
Based on fundamental analysis, Sutro Biopharma, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sutro Biopharma, Inc.. Balance Sheet: STRO Debt, Cash & Liquidity
STRO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sutro Biopharma, Inc..'s revenue has grown significantly by 66% over the 5-year period, indicating strong business expansion. The most recent EPS of $-29.40 indicates the company is currently unprofitable.
STRO Revenue Growth, EPS Growth & YoY Performance
STRO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $14.5M | -$38.5M | $-2.94 |
| Q3 2025 | $8.5M | -$11.5M | $-0.59 |
| Q2 2025 | $25.7M | -$11.5M | $-0.14 |
| Q1 2025 | $13.0M | -$58.2M | $-0.91 |
| Q3 2024 | $8.5M | -$38.5M | $-0.59 |
| Q2 2024 | $10.4M | -$38.5M | $-0.59 |
| Q1 2024 | $12.7M | -$50.1M | $-0.85 |
| Q3 2023 | $16.9M | -$19.5M | $-0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sutro Biopharma, Inc.. Dividends, Buybacks & Capital Allocation
STRO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sutro Biopharma, Inc.. (CIK: 0001382101)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STRO
What is the AI rating for STRO?
Sutro Biopharma, Inc.. (STRO) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STRO's key strengths?
Claude: Revenue growth of 65.2% YoY demonstrates commercial traction and market acceptance. Adequate short-term liquidity with $73.7M cash and 3.12x current ratio.
What are the risks of investing in STRO?
Claude: Negative stockholders' equity of -$66.9M indicates technical insolvency on book value basis. Operating cash burn of -$43M annually against only $73.7M cash creates <2 year survival window.
What is STRO's revenue and growth?
Sutro Biopharma, Inc.. reported revenue of $14.5M.
Does STRO pay dividends?
Sutro Biopharma, Inc.. does not currently pay dividends.
Where can I find STRO SEC filings?
Official SEC filings for Sutro Biopharma, Inc.. (CIK: 0001382101) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STRO's EPS?
Sutro Biopharma, Inc.. has a diluted EPS of $-2.94.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is STRO's fundamental grade?
Based on our AI fundamental analysis in May 2026, Sutro Biopharma, Inc.. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is STRO stock overvalued or undervalued?
Valuation metrics for STRO: ROE of N/A (sector avg: 15%), net margin of -265.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is STRO's AI grade for 2026?
Our dual AI analysis gives Sutro Biopharma, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STRO's free cash flow?
Sutro Biopharma, Inc..'s operating cash flow is $-42.3M, with capital expenditures of $763.0K. FCF margin is -296.2%.
How does STRO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -265.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 3.12 (avg: 2).